{"id":"https://openalex.org/W2017999211","doi":"https://doi.org/10.3851/imp2689","title":"Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761)","display_name":"Unexpected Finding of Delayed-Onset Seizures in HIV-Positive, Treatment-Experienced Subjects in the Phase Iib Evaluation of Fosdevirine (Gsk2248761)","publication_year":2013,"publication_date":"2013-10-25","ids":{"openalex":"https://openalex.org/W2017999211","doi":"https://doi.org/10.3851/imp2689","mag":"2017999211","pmid":"https://pubmed.ncbi.nlm.nih.gov/24158593"},"language":"en","primary_location":{"id":"doi:10.3851/imp2689","doi":"https://doi.org/10.3851/imp2689","is_oa":true,"landing_page_url":"https://doi.org/10.3851/imp2689","pdf_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2689","source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"bronze","oa_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2689","any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5104021287","display_name":"David A. Margolis","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":true,"raw_author_name":"David A Margolis","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5024560316","display_name":"Joseph J. Eron","orcid":"https://orcid.org/0000-0002-4938-0644","observed_orcids":["https://orcid.org/0000-0002-4938-0644"]},"institutions":[{"id":"https://openalex.org/I114027177","display_name":"University of North Carolina at Chapel Hill","ror":"https://ror.org/0130frc33","country_code":"US","type":"education","lineage":["https://openalex.org/I114027177"]},{"id":"https://openalex.org/I1333535994","display_name":"University of North Carolina Health Care","ror":"https://ror.org/00qz24g20","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1333535994"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Joseph J Eron","raw_affiliation_strings":["Center for AIDS Research Clinical Core, UNC School of Medicine, Chapel Hill, NC, USA","Infectious Diseases"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Center for AIDS Research Clinical Core, UNC School of Medicine, Chapel Hill, NC, USA","institution_ids":["https://openalex.org/I114027177","https://openalex.org/I1333535994"]},{"raw_affiliation_string":"Infectious Diseases","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103806974","display_name":"Edwin DeJesus","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210120784","display_name":"Orlando Immunology Center","ror":"https://ror.org/02cj88v79","country_code":"US","type":"facility","lineage":["https://openalex.org/I4210120784"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Edwin DeJesus","raw_affiliation_strings":["Orlando Immunology Center, Orlando, FL, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Orlando Immunology Center, Orlando, FL, USA","institution_ids":["https://openalex.org/I4210120784"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5054782560","display_name":"Scott White","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Scott White","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5061912045","display_name":"Paul G. Wannamaker","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Paul Wannamaker","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, NC, USA","institution_ids":[]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5014972896","display_name":"Britt S. Stancil","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Britt Stancil","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, NC, USA","institution_ids":[]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5068528879","display_name":"Mark Johnson","orcid":"https://orcid.org/0000-0002-0747-9697","observed_orcids":["https://orcid.org/0000-0002-0747-9697"]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Mark Johnson","raw_affiliation_strings":["GlaxoSmithKline, Research Triangle Park, NC, USA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"GlaxoSmithKline, Research Triangle Park, NC, USA","institution_ids":[]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5104021287"],"corresponding_institution_ids":[],"apc_list":{"value":2800,"currency":"USD","value_usd":2800},"apc_paid":null,"fwci":0.6814,"has_fulltext":true,"cited_by_count":14,"citation_normalized_percentile":{"value":0.70410697,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":89,"max":97},"biblio":{"volume":"19","issue":"1","first_page":"69","last_page":"78"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10526","display_name":"HIV/AIDS drug development and treatment","score":0.9980000257492065,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10112","display_name":"HIV Research and Treatment","score":0.000699999975040555,"subfield":{"id":"https://openalex.org/subfields/2406","display_name":"Virology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10094","display_name":"Epilepsy research and treatment","score":0.00019999999494757503,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Clinical Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/new-onset-seizures","display_name":"new-onset seizures","score":0.7080000042915344},{"id":"https://openalex.org/keywords/hiv-1","display_name":"HIV-1","score":0.7549999952316284},{"id":"https://openalex.org/keywords/non-nucleoside-reverse-transcriptase-inhibitors","display_name":"non-nucleoside reverse transcriptase inhibitors","score":0.8980000019073486},{"id":"https://openalex.org/keywords/efavirenz-resistance","display_name":"efavirenz resistance","score":0.8790000081062317},{"id":"https://openalex.org/keywords/antiretroviral-drug-safety","display_name":"antiretroviral drug safety","score":0.8180000185966492},{"id":"https://openalex.org/keywords/adverse-drug-reactions","display_name":"adverse drug reactions","score":0.4729999899864197},{"id":"https://openalex.org/keywords/medication-discontinuation","display_name":"drug discontinuation","score":0.4790000021457672}],"concepts":[{"id":"https://openalex.org/C2781432083","wikidata":"https://www.wikidata.org/wiki/Q422645","display_name":"Efavirenz","level":5,"score":0.7847583293914795},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.702003002166748},{"id":"https://openalex.org/C2779465607","wikidata":"https://www.wikidata.org/wiki/Q304330","display_name":"Abacavir","level":5,"score":0.6407302618026733},{"id":"https://openalex.org/C2780404665","wikidata":"https://www.wikidata.org/wiki/Q421552","display_name":"Raltegravir","level":5,"score":0.6005013585090637},{"id":"https://openalex.org/C2779182219","wikidata":"https://www.wikidata.org/wiki/Q3765251","display_name":"Darunavir","level":5,"score":0.5934139490127563},{"id":"https://openalex.org/C2777869810","wikidata":"https://www.wikidata.org/wiki/Q422631","display_name":"Lamivudine","level":4,"score":0.5624039173126221},{"id":"https://openalex.org/C2779778239","wikidata":"https://www.wikidata.org/wiki/Q422604","display_name":"Emtricitabine","level":5,"score":0.558340847492218},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.5450520515441895},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.5387483835220337},{"id":"https://openalex.org/C2777351918","wikidata":"https://www.wikidata.org/wiki/Q421559","display_name":"Reverse-transcriptase inhibitor","level":5,"score":0.5071768760681152},{"id":"https://openalex.org/C2779298103","wikidata":"https://www.wikidata.org/wiki/Q422618","display_name":"Ritonavir","level":5,"score":0.5062353014945984},{"id":"https://openalex.org/C90924648","wikidata":"https://www.wikidata.org/wiki/Q120569","display_name":"Gastroenterology","level":1,"score":0.4522342383861542},{"id":"https://openalex.org/C2780345285","wikidata":"https://www.wikidata.org/wiki/Q414762","display_name":"Etravirine","level":5,"score":0.4398248791694641},{"id":"https://openalex.org/C168563851","wikidata":"https://www.wikidata.org/wiki/Q1436668","display_name":"Randomized controlled trial","level":2,"score":0.42732903361320496},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.42174485325813293},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.399029016494751},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.30232691764831543},{"id":"https://openalex.org/C142462285","wikidata":"https://www.wikidata.org/wiki/Q2528140","display_name":"Viral load","level":3,"score":0.21860945224761963},{"id":"https://openalex.org/C159047783","wikidata":"https://www.wikidata.org/wiki/Q7215","display_name":"Virology","level":1,"score":0.16574254631996155},{"id":"https://openalex.org/C2776452011","wikidata":"https://www.wikidata.org/wiki/Q311463","display_name":"Sida","level":4,"score":0.16374871134757996},{"id":"https://openalex.org/C3013748606","wikidata":"https://www.wikidata.org/wiki/Q15787","display_name":"Human immunodeficiency virus (HIV)","level":2,"score":0.14752760529518127},{"id":"https://openalex.org/C2780727368","wikidata":"https://www.wikidata.org/wiki/Q1928978","display_name":"Viral disease","level":3,"score":0.1446371078491211},{"id":"https://openalex.org/C2993143319","wikidata":"https://www.wikidata.org/wiki/Q583050","display_name":"Antiretroviral therapy","level":4,"score":0.0},{"id":"https://openalex.org/C2522874641","wikidata":"https://www.wikidata.org/wiki/Q808","display_name":"Virus","level":2,"score":0.0},{"id":"https://openalex.org/C2780593183","wikidata":"https://www.wikidata.org/wiki/Q6844","display_name":"Hepatitis B virus","level":3,"score":0.0}],"mesh":[{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D007211","descriptor_name":"Indoles","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D010721","descriptor_name":"Phosphinic Acids","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":false},{"descriptor_ui":"D010721","descriptor_name":"Phosphinic Acids","qualifier_ui":"Q000493","qualifier_name":"pharmacokinetics","is_major_topic":false},{"descriptor_ui":"D010721","descriptor_name":"Phosphinic Acids","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D012640","descriptor_name":"Seizures","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D013997","descriptor_name":"Time Factors","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015497","descriptor_name":"HIV-1","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000150","qualifier_name":"complications","is_major_topic":true},{"descriptor_ui":"D015658","descriptor_name":"HIV Infections","qualifier_ui":"Q000188","qualifier_name":"drug therapy","is_major_topic":true},{"descriptor_ui":"D016896","descriptor_name":"Treatment Outcome","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D018894","descriptor_name":"Reverse Transcriptase Inhibitors","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000494","qualifier_name":"pharmacology","is_major_topic":false},{"descriptor_ui":"D019380","descriptor_name":"Anti-HIV Agents","qualifier_ui":"Q000627","qualifier_name":"therapeutic use","is_major_topic":true},{"descriptor_ui":"D028761","descriptor_name":"Withholding Treatment","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D057915","descriptor_name":"Drug Substitution","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":2,"locations":[{"id":"doi:10.3851/imp2689","doi":"https://doi.org/10.3851/imp2689","is_oa":true,"landing_page_url":"https://doi.org/10.3851/imp2689","pdf_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2689","source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},{"id":"pmid:24158593","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/24158593","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral therapy","raw_type":"Clinical Trial, Phase II"}],"best_oa_location":{"id":"doi:10.3851/imp2689","doi":"https://doi.org/10.3851/imp2689","is_oa":true,"landing_page_url":"https://doi.org/10.3851/imp2689","pdf_url":"https://journals.sagepub.com/doi/pdf/10.3851/IMP2689","source":{"id":"https://openalex.org/S137629795","display_name":"Antiviral Therapy","issn_l":"1359-6535","issn":["1359-6535","2040-2058"],"is_oa":false,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","doyens","jufo-1","ki-jl-1","medline","norway-1","poland-140","russia-white-list-2"],"host_organization":"https://openalex.org/P4310320017","host_organization_name":"SAGE Publishing","host_organization_lineage":["https://openalex.org/P4310320017"],"host_organization_lineage_names":["SAGE Publishing"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Antiviral Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"score":1.0,"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being"}],"study_designs":[],"awards":[{"id":"https://openalex.org/G9000894295","display_name":"The University of North Carolina Center for AIDS Research","funder_award_id":"P30AI050410","funder_id":"https://openalex.org/F4320337355","funder_display_name":"National Institute of Allergy and Infectious Diseases"}],"funders":[{"id":"https://openalex.org/F4320312382","display_name":"ViiV Healthcare","ror":"https://ror.org/01cc9yk21"},{"id":"https://openalex.org/F4320337355","display_name":"National Institute of Allergy and Infectious Diseases","ror":"https://ror.org/043z4tv69"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W2017999211.pdf","grobid_xml":"https://content.openalex.org/works/W2017999211.grobid-xml"},"referenced_works_count":20,"referenced_works":["https://openalex.org/W1480425134","https://openalex.org/W1550070317","https://openalex.org/W1968922673","https://openalex.org/W1969836710","https://openalex.org/W1991518353","https://openalex.org/W2028972769","https://openalex.org/W2030201426","https://openalex.org/W2031197667","https://openalex.org/W2034666554","https://openalex.org/W2039316604","https://openalex.org/W2047838688","https://openalex.org/W2048201822","https://openalex.org/W2061678383","https://openalex.org/W2082888182","https://openalex.org/W2086130827","https://openalex.org/W2089024889","https://openalex.org/W2128912768","https://openalex.org/W2148683493","https://openalex.org/W2166691466","https://openalex.org/W2215130966"],"related_works":["https://openalex.org/W2318278245","https://openalex.org/W2039316604","https://openalex.org/W2154217492","https://openalex.org/W2083359555","https://openalex.org/W2166691466","https://openalex.org/W2078196676","https://openalex.org/W2538828749","https://openalex.org/W2153034726","https://openalex.org/W1979465503","https://openalex.org/W2468431289"],"abstract_inverted_index":{"BACKGROUND:":[0],"Fosdevirine":[1],"(GSK2248761)":[2],"is":[3,230],"a":[4,37],"non-nucleoside":[5,89],"reverse":[6,90],"transcriptase":[7,91],"inhibitor":[8],"with":[9,33,70,88,99,115,134],"HIV-1":[10,93,135],"activity":[11],"against":[12],"common":[13],"efavirenz-resistant":[14],"strains.":[15],"Two":[16],"partially":[17],"blind,":[18],"randomized,":[19],"Phase":[20,43],"IIb":[21],"studies":[22],"were":[23,53,94,141,150,159],"initiated":[24],"(1":[25,165],"in":[26,30,233],"treatment-naive":[27,51],"and":[28,120,139,192,207,226,241],"1":[29],"treatment-experienced":[31,86,163],"subjects":[32,52,87,133,149,164,210],"HIV)":[34],"to":[35,56,97,152,183,198,204,238],"select":[36],"once-daily":[38,58],"dose":[39],"of":[40,132,147,181,221],"fosdevirine":[41,59,100,153,167,172,193,224],"for":[42,245],"III":[44],"trials.":[45],"METHODS:":[46],"In":[47,82],"the":[48,83,130,243],"SIGNET":[49],"study,":[50,85],"randomized":[54,95],"1:1:1":[55,96],"receive":[57],"100":[60,101,154,168],"or":[61,64,77,102,107,155],"200":[62,103,109,156,173],"mg":[63,76,104,110,119],"efavirenz":[65],"600":[66,79],"mg,":[67,169],"each":[68,113],"along":[69,114],"tenofovir":[71],"disoproxil":[72],"fumarate/emtricitabine":[73],"300":[74],"mg/200":[75],"abacavir/lamivudine":[78],"mg/300":[80],"mg.":[81,123,157],"SONNET":[84],"inhibitor-resistant":[92],"treatment":[98],"once":[105],"daily":[106],"etravirine":[108],"twice":[111],"daily,":[112],"twice-daily":[116],"darunavir/ritonavir":[117],"600/100":[118],"raltegravir":[121],"400":[122],"The":[124,218],"primary":[125],"efficacy":[126],"end":[127],"point":[128],"was":[129,186],"proportion":[131],"RNA<50":[136],"copies/ml.":[137],"Safety":[138],"pharmacokinetics":[140],"also":[142],"addressed.":[143],"RESULTS:":[144],"A":[145],"total":[146],"35":[148],"exposed":[151],"Trials":[158],"halted":[160],"when":[161],"5":[162,209],"receiving":[166,171],"4":[170],"mg)":[174],"developed":[175],"new-onset":[176],"seizures":[177,191,222],"after":[178,214,223,228],"\u22654":[179],"weeks":[180],"exposure":[182,225],"fosdevirine.":[184],"There":[185],"no":[187],"clear":[188],"association":[189],"between":[190],"plasma":[194],"drug":[195,215,235],"levels.":[196],"Time":[197],"seizure":[199,213],"onset":[200,220],"ranged":[201],"from":[202],"28":[203],"81":[205],"days,":[206],"all":[208],"experienced":[211],"\u22651":[212],"discontinuation.":[216],"CONCLUSIONS:":[217],"delayed":[219],"persistence":[227],"discontinuation":[229],"without":[231],"precedent":[232],"antiretroviral":[234],"development,":[236],"leading":[237],"additional":[239],"investigation":[240],"underscoring":[242],"need":[244],"careful":[246],"subject":[247],"monitoring.":[248]},"counts_by_year":[{"year":2026,"cited_by_count":1},{"year":2025,"cited_by_count":3},{"year":2024,"cited_by_count":1},{"year":2022,"cited_by_count":2},{"year":2021,"cited_by_count":2},{"year":2020,"cited_by_count":2},{"year":2019,"cited_by_count":1},{"year":2014,"cited_by_count":1},{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-31T12:09:11.096373","created_date":"2016-06-24T00:00:00"}